Sample Characteristics
A total of 2372 adult HIV-infected pregnant women with no more than 32 weeks of gestation were screened for study eligibility across the eight study sites; 694 (29.3%) screened positive on the PHQ-2, of whom 627 (90.3%) expressed interest in study participation and were further evaluated for eligibility. Of these 627, 586 (93.5%) were medically stable and therefore administered the PHQ-9; 465 of the 586 women (79.4%) scored > 4 on the PHQ-9 and were eligible, of whom 404 expressed interest in study participation and were referred to the study coordinator for consent procedures. Of these 404, 391 (96.8%) agreed to enroll in the study and comprised the analytic sample (see Fig. Flow of participants from screening and enrollment to the two-month post-pregnancy (PP) assessmentOf the 391 enrolled women, 50 were enrolled at each of 7 of the 8 study sites, while the eighth site enrolled 41 (200 at control sites; 191 at intervention sites). Table Sample characteristics at baseline by study arm and completion of the 2-month post-pregnancy (PP) assessmentBolded numbers represent values that are statistically significant (